In contrast, Hirashima et al. analyzed a group of 29 NSCLC patients receiving ICI treatment and observed that patients with low levels of IFN-gamma (<10 IU/mL) tend to experience poor response and early disease progression [152]. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.